Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.

Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ.

Exp Hematol. 2011 Jan;39(1):14-25. doi: 10.1016/j.exphem.2010.09.013. Epub 2010 Oct 8.

PMID:
20934482
2.

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.

Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z.

Clin Cancer Res. 2008 Feb 1;14(3):788-96. doi: 10.1158/1078-0432.CCR-07-0524.

3.

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.

Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J, Su N, Wang T, Ioannidis S, Davies A, Huszar D, Zinda M.

J Biol Chem. 2008 Nov 21;283(47):32334-43. doi: 10.1074/jbc.M803813200. Epub 2008 Sep 4.

4.

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.

Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S.

Invest New Drugs. 2011 Oct;29(5):818-26. doi: 10.1007/s10637-010-9429-z. Epub 2010 Apr 7.

5.

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T.

Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29.

6.

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.

Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S.

Cancer Sci. 2008 Jun;99(6):1265-73. doi: 10.1111/j.1349-7006.2008.00817.x.

7.

Imatinib effect on growth and signal transduction in polycythemia vera.

Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT.

Exp Hematol. 2007 Jun;35(6):931-8.

PMID:
17533047
8.

An inhibitor of Janus kinase 2 prevents polycythemia in mice.

Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, Young J, Zhao S, Wang Y, Kopinja J, Qu X, Reilly J, Walker D, Xu L, Aleksandrowicz D, Marshall G, Scott ML, Kohl NE, Bachman E.

Biochem Pharmacol. 2009 Aug 15;78(4):382-9. doi: 10.1016/j.bcp.2009.04.025. Epub 2009 May 3.

PMID:
19413997
9.

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.

Ueda F, Sumi K, Tago K, Kasahara T, Funakoshi-Tago M.

Cell Signal. 2013 Nov;25(11):2115-24. doi: 10.1016/j.cellsig.2013.07.003. Epub 2013 Jul 6.

PMID:
23838005
10.

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.

Clin Cancer Res. 2009 Nov 15;15(22):6891-900. doi: 10.1158/1078-0432.CCR-09-1298. Epub 2009 Nov 3.

11.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A.

Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31.

PMID:
17541402
12.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
13.

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.

Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, Shi G, Wang W, Shi J, Zhang T.

J Exp Clin Cancer Res. 2019 Feb 4;38(1):49. doi: 10.1186/s13046-019-1062-x.

14.

The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.

Abe M, Funakoshi-Tago M, Tago K, Kamishimoto J, Aizu-Yokota E, Sonoda Y, Kasahara T.

Int Immunopharmacol. 2009 Jul;9(7-8):870-7. doi: 10.1016/j.intimp.2009.03.011. Epub 2009 Mar 25.

PMID:
19327411
15.

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN.

Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29.

PMID:
22378845
16.

The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V.

Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7.

PMID:
22065597
17.

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.

PMID:
20870899
18.

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.

Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K.

Blood. 2011 Jun 23;117(25):6866-75. doi: 10.1182/blood-2010-01-262535. Epub 2011 Apr 29.

PMID:
21531978
19.

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.

Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, Neri A, Finazzi G, Mantovani R, Rambaldi A, Introna M, Lombardi L, Golay J; AGIMM Investigators.

Exp Hematol. 2012 Aug;40(8):634-45.e10. doi: 10.1016/j.exphem.2012.04.007. Epub 2012 May 8.

PMID:
22579713
20.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

Supplemental Content

Support Center